The blood sugar-lowering drug semaglutide, marketed as 'Ozempic' by Novo Nordisk, is prescribed not only for treating type 2 diabetes but also to aid weight loss in obese individuals with very high body mass indexes. However, health insurers in the U.S. often refuse to cover the costs of this long-term medication. According to Reuters, one case involves a 46-year-old woman who requested to be identified only by her first name, Shante. With the help of Ozempic, she has managed to lose 50 pounds over two years, although her health insurance has informed her that it will not cover her weight loss treatment. Shante, who is under her husband’s insurance plan from Warner Bros. Discovery, states that she was told she is not eligible for Ozempic because she does not have diabetes. The newer and more expensive version of this drug, called 'Wegovy', specifically for weight loss, was approved by U.S. health regulators in 2021. However, Warner Bros. only agreed to cover the cost of Wegovy after Shante's husband filed a complaint with the company's human resources department and a lawyer insisted on its coverage. Warner Bros. Discovery did not respond to Reuters' request for comment. More employers are now supporting treatments that can reduce the risk of diseases such as heart disease and diabetes, which can be exacerbated by obesity. The drugs 'Wegovy' and 'Mounjaro' (a similar diabetes treatment from Eli Lilly) have been used off-label and are not yet approved for weight loss, but they have made an impact. Both drugs have shown in clinical trials that they help individuals lose about 15% of their weight. However, according to information published on pharmaceutical company websites, their cost is about $1,000 per month, and patients likely need to use these drugs indefinitely for weight loss. Research from the British public company Barclays has shown that the use of Wegovy for weight loss has increased from 45,000 prescriptions per week at the end of January to 135,000 new prescriptions per week in May, and it is expected to rise even further.
Popularity of 'Wegovy' Weight Loss Drug; American Insurers: We Do Not Cover It
The weight loss drug Wegovy is gaining popularity, but many American insurers refuse to cover its costs, affecting patients like Shante who have successfully lost weight using it. This situation highlights the challenges of accessing necessary medications for weight loss in the U.S. healthcare system.
👥 Key Players
📰 What Happened
Shante, a patient who lost weight using Ozempic, faced challenges getting her insurance to cover Wegovy, a newer weight loss drug. After advocacy, her employer agreed to cover the medication, highlighting issues with insurance coverage for weight loss treatments.
- Wegovy and Mounjaro have shown clinical effectiveness in weight loss.
- The cost of these medications is approximately $1,000 per month.
💡 Why It Matters
📚 Background
Weight loss drugs have become increasingly popular in the U.S. as obesity rates rise, yet insurance coverage remains inconsistent. This reflects broader issues of healthcare affordability and access.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 85%